Anoikis resistance as a key driver of glioma malignancy: From ECM detachment to potential druggable targets
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189608
DOI: 10.1016/j.bbcan.2026.189608 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Yuheng Zou und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Anoikis, Glioma, Extracellular Matrix, Brain Neoplasms. Die Arbeit nennt 304 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Provincial Natural Science Foundation, Administration of Traditional Chinese Medicine of Jilin Province.
Abstract (Originalsprache)
Gliomas, particularly glioblastoma multiforme (GBM), represent the most predominant and aggressive primary central nervous system (CNS) tumors, with treatment challenges stemming from their invasiveness and high recurrence. Anoikis is a form of programmed cell death triggered by detachment from the extracellular matrix. Normal cells typically undergo self-elimination, while glioma and other cancer cells often subvert this process through acquired anoikis resistance, enabling sustained anchorage-independent survival and proliferation. This resistance is a key driver of invasion, metastasis, and recurrence. Here, we outline recent advances in morphological and ultrastructural modifications, molecular, and signaling mechanisms governing anoikis and its resistance in malignant cells, with a focus on their specific pathophysiological role in glioma pathogenesis and progression. The experimental platforms are also discussed. Furthermore, we summarize emerging therapeutic strategies targeting anoikis resistance to provide a framework for understanding its contribution to glioma stem cell (GSC) origination, invasion and metastasis, treatment resistance, and recurrence, thereby informing novel therapeutic strategies for GBM and other cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China.
- School of Engineering, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong Special Administrative Region.
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China. Electronic address: wqrui@smu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Guangdong Provincial Natural Science Foundation
- Administration of Traditional Chinese Medicine of Jilin Province
Zitieren
APA
Zou, Y., Zou, C., Huang, X., Zhu, Y., & Wang, Q. (2026). Anoikis resistance as a key driver of glioma malignancy: From ECM detachment to potential druggable targets. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189608. https://doi.org/10.1016/j.bbcan.2026.189608
Vancouver
Zou Y, Zou C, Huang X, Zhu Y, Wang Q. Anoikis resistance as a key driver of glioma malignancy: From ECM detachment to potential druggable targets. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189608. doi:10.1016/j.bbcan.2026.189608
BibTeX
@article{Zou2026,
author = {Zou, Yuheng and Zou, Chen and Huang, Xiumei and Zhu, Yipeng and Wang, Qirui},
title = {Anoikis resistance as a key driver of glioma malignancy: From ECM detachment to potential druggable targets},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {4},
pages = {189608},
doi = {10.1016/j.bbcan.2026.189608}
}
EUVIMED